

# Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 18 January 2021

Situation Report No. 217 - Kingdom of Bahrain  
19<sup>th</sup> of January, 2021



	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
<b>Total</b>	93,956,883	2,029,084	5,382,718	128,644
<b>New</b>	588,325	11,136	25,231	410

## Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
<b>Total</b>	97,940	94,646	360	2,934	16	2,563,504
<b>New</b>	333	349	0	-	-	10,803

## HIGHLIGHTS

- Increasing number of citizens and residents continue to take COVID-19 vaccine in Bahrain; and Ministry of Health (MOH) revealed that total number of individuals vaccinated as of 18 January 2021 is 142,831.
- MOH announced that COVID-19 Mobile Vaccination Units are being rolled out across the kingdom for the elderly and people with special needs.
- MOH urged people who have taken the first dose of COVID-19 vaccine to schedule to receive the second dose in 21 days.
- MOH Undersecretary urges for full compliance with precautionary measures especially amid the pandemic spike.
- Bahrain's court system heard a total of 681 cases of people breaking COVID-19 public health measures last year.
- COVID-19 vaccines will soon be administered through private healthcare facilities in the country.
- WHO: New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies; see link below.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immun assay; see link below.
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19; see link below.
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises; see link below.
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021; see link below.
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health; see link below.
- WHO: Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing; see link below.
- WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum; see link below.
- WHO: Draft landscape of COVID-19 candidate vaccines; see link below.
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers; see link below.
- WHO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19; see link below.
- WHO: Scientists tackle vaccine safety, efficacy and access at global R&D forum; see link below.
- WHO: Emergency Committee on COVID-19 advises on variants, vaccines; see link below.
- WHO: Statement on the sixth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic; see link below.


## IMPORTANT LINKS

- Daily COVID-19 updates on MOH website: <https://www.moh.gov.bh/>
- WHO's COVID-19 weekly situation reports: [https://www.who.int/docs/default-source/coronavirus/situation-reports/20200817-weekly-epi-update-1.pdf?sfvrsn=b6449a76\\_4](https://www.who.int/docs/default-source/coronavirus/situation-reports/20200817-weekly-epi-update-1.pdf?sfvrsn=b6449a76_4)
- WHO's COVID-19 Dashboard: <https://covid19.who.int/>
- WHO: New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies: <https://www.who.int/news/item/09-01-2021-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies>
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic: <https://bit.ly/25vtd0r>
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue: <https://www.who.int/publications/item/emergency-global-supply-chain-system-covid-19-catalogue>
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immun assay: <https://bit.ly/2R0fVf>
- WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination: <https://bit.ly/2J0wXWQ>
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: [https://www.who.int/publications/item/WHO-2019-nCoV-HEI\\_Assessment-Products-2021.1](https://www.who.int/publications/item/WHO-2019-nCoV-HEI_Assessment-Products-2021.1)
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises: <https://www.who.int/publications/item/9789240017467>
- COVID-19 vaccine introduction and deployment costing tool: <https://www.who.int/publications/item/1066533753>
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding: [https://www.who.int/publications/item/WHO-2019-nCoV-Polcy\\_Brief\\_EUD\\_placebo-controlled\\_vaccine\\_trials-2020.1](https://www.who.int/publications/item/WHO-2019-nCoV-Polcy_Brief_EUD_placebo-controlled_vaccine_trials-2020.1)
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19: [https://www.who.int/publications/item/WHO-2019-nCoV-Risk-based\\_International\\_Travel\\_Assessment\\_tool-2020.1](https://www.who.int/publications/item/WHO-2019-nCoV-Risk-based_International_Travel_Assessment_tool-2020.1)
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021: <https://www.who.int/news/item/18-12-2020-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021>
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access: <https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health: <https://www.who.int/publications/item/9789240018440>
- WHO: Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing: [https://www.who.int/publications/item/WHO-2019-nCoV-vaccines-SAGE\\_recommendation-BNT162b2-2021.1](https://www.who.int/publications/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1)
- WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum: <https://www.who.int/news/item/12-01-2021-global-scientists-double-down-on-sars-cov-2-variants-research-at-who-hosted-forum>
- WHO: Draft landscape of COVID-19 candidate vaccines: <https://www.who.int/publications/item/item/draft-landscape-of-covid-19-candidate-vaccines>
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers: [https://www.who.int/publications/item/WHO-2019-nCoV-essential\\_health\\_services-monitoring-2021.1](https://www.who.int/publications/item/WHO-2019-nCoV-essential_health_services-monitoring-2021.1)
- WHO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19: <https://www.who.int/publications/item/background-document-on-mrna-vaccine-bnt162b2-pfizer-biontech-against-covid-19>
- WHO: Scientists tackle vaccine safety, efficacy and access at global R&D forum: <https://www.who.int/news/item/16-01-2021-scientists-tackle-vaccine-safety-efcacy-and-access-at-global-r-d-forum>
- WHO: Emergency Committee on COVID-19 advises on variants, vaccines: <https://www.who.int/news/item/15-01-2021-emergency-committee-on-covid-19-advises-on-variants-vaccines>
- WHO: Statement on the sixth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic: <https://www.who.int/news/item/15-01-2021-statement-on-the-sixth-meeting-of-the-international-health-regulations-2005-emergency-committee-regarding-the-coronavirus-disease-covid-19-pandemic>


## IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: [NAI5@health.gov.bh](mailto:NAI5@health.gov.bh)
- International Health Regulations focal person is Dr. Kubra Salman, email: [knasser@health.gov.bh](mailto:knasser@health.gov.bh)

Number of New Cases



Total Number of Cases



Number of New Deaths

